ML
Therapeutic Areas
Neurocrine Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INGREZZA (valbenazine) | Tardive Dyskinesia | Approved |
| Crinecerfont (NBI-74788) | Congenital Adrenal Hyperplasia | Phase 3 |
| NBI-827104 | Essential Tremor | Phase 2 |
| INGREZZA | Tourette Syndrome | Phase 3 |
| Luvadaxistat (NBI-1065845) | Schizophrenia | Phase 2 |
| NBI-921352 | Epilepsy | Phase 2 |
Leadership Team at Neurocrine Biosciences
KG
Kevin Gorman
Chief Executive Officer
MA
Matt Abernethy
Chief Financial Officer
ER
Eiry Roberts
Chief Medical Officer
KG
Kyle Gano
Chief Commercial Officer
CO
Christopher O'Brien
Chief Scientific Officer
TC
Tim Coughlin
Chief Human Resources Officer